Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260047 · ClinicalTrials.gov registry record · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
A NA study of Opioid Use and Substance Use, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 525
- Enrollment target
- 8
- Study locations
NCT05260047: Recruiting NA study of Opioid Use and Substance Use, sponsored by Yale University.
NCT05260047 is a NA study of Opioid Use and Substance Use that is actively recruiting participants, run by Yale University. The registered enrollment target is 525 participants, below the 148,255-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower). The trial reports 8 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05260047, a NA study of Opioid Use and Substance Use, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 525 participants
- Enrollment target
- 8
- Study locations
Study Summary
The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
Primary Outcome
The total number of sessions that participants attend will be used to measure continuation of program.
Conditions Studied
Interventions
- BEHAVIORAL IMANI
- BEHAVIORAL Telehealth MAT
- BEHAVIORAL Traditional MAT plus Referral and Linkage
Study Locations (8)
Connecticut
- Mount Aery Baptist Church - Bridgeport
- Principe of Peace Church - Bridgeport
- Blackwell Memorial AME Church - Hartford
- Iglesia Nuevo Comienzo - Hartford
- Spottswood AME - New Britain
- Varick Memorial AME Church - New Haven
- Yale Program for Recovery and Community Health - New Haven
- Casa de Oracion y Adoracion - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
What NCT05260047 shows while recruiting
NCT05260047 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, below the 148,255-participant average among 105 other Opioid Use trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Opioid Use appearing as the primary indexed condition, and to 3 interventions - of which IMANI is the first listed.
NCT05260047 lists 8 locations in 1 state (Connecticut).
Frequently Asked Questions
What is clinical trial NCT05260047 about?
NCT05260047 is a clinical study titled "Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population". The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
What is the current status of trial NCT05260047?
This trial is currently recruiting. It is a NA study. The enrollment target is 525 participants. The study started on 2022-07-20. Estimated completion is 2026-10-01.
What conditions does trial NCT05260047 study?
This clinical trial studies the following conditions: Opioid Use, Substance Use, Mental Health Issue, Medication Assisted Treatment.
What interventions are being tested in trial NCT05260047?
The interventions under investigation include: IMANI (BEHAVIORAL), Telehealth MAT (BEHAVIORAL), Traditional MAT plus Referral and Linkage (BEHAVIORAL).
Who is sponsoring clinical trial NCT05260047?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05260047 being conducted?
This trial has 8 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05260047's enrollment target sits among peer trials
525 16th of 105 higher than 90 of 105 other Opioid Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
QL vs LAI for Palatoplasty
RECRUITING · NA
-
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
RECRUITING · NA
-
Hip Arthroscopy Postoperative Opioid Demands
RECRUITING · NA
-
Neuroimaging of Opioid Phase (OPAL)
RECRUITING · NA
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Opioid Prescribing Practices in Laparoscopic Gynecologic Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
- NCT04738825 · 526 participants · NA
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI